Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX221 in Refractory Gout
NCT05800041Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
01
Overview
Phase 1, open-label trial of WTX221 in gout (3 arms), sponsored by Renji Hospital. Primary endpoint: Safety and tolerability of multiple doses of WTX221 infusion combined with cyclophosphamide at 210 days. Status: unknown.
02
Drugs
WTX221
03
Conditions
gout
Beyond the preview
Go deeper on NCT05800041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800041.